Arovella takes a punt on new cytokine technology

2 minute read


The Melbourne biotech has signed an exclusive license agreement with the University of North Carolina.


The Melbourne biotech has signed an exclusive license agreement with the University of North Carolina.

This content is for Health Services Daily members only.
Login or Join Now.

End of content

No more pages to load

Log In Register ×